Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease

Fig. 2

GOLDEN 7 study schematic. Washout of more than 7 days required approval by the Sponsor. All doses were administered at the same time of day (± 1 h), 7 days apart. aSubjects had follow-up telephone contact on Day 36 (± 1 day) to assess safety. Subjects who discontinued prior to Visit 6 had follow-up telephone contact 5 to 7 days after their last study treatment. EOT, end of treatment

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us